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Protein kinases are central components of signal transduction cascades often dysregulated in cancer, and
they represent some of the most promising drug targets. However, the target selectivity is a major concern
because most described kinase inhibitors target the highly conserved ATP-binding pocket. Recently, new
classes of inhibitors that do not compete with ATP and exhibit different mechanisms of action have been
described. Overexpression of protein kinase CK2 is an unfavorable prognostic marker in several cancers.
Consequently, CK2 has emerged as a relevant therapeutic target. Several classes of ATP-competitive inhib-
itors have been identified, showing variable effectiveness. The molecular architecture of this multisubunit
enzyme could offer alternative strategies to inhibit CK2 functions, and this review illustrates these emerging
possibilities.Introduction
Protein phosphorylation is a recurrent theme in biology and is
recognized as a major regulatory device that controls nearly all
aspects of cellular growth, division, and differentiation. This
reversible protein modification is catalyzed by protein kinases.
These enzymes use ATP, as a phosphate group donor, and
protein alcohol groups (on serine and threonine) and phenolic
groups (on tyrosine), as phosphate group acceptors, to generate
phosphate monoesters. In eukaryotic cells, protein kinases are
central components of signaling pathways regulating cellular
homeostasis. Unfortunatly, perturbation of protein kinase-medi-
ated signaling networks can lead to various disease states.
Therefore, protein kinases have emerged as some of the most
promissing drug targets. Indeed, diverse strategies to inhibit
protein kinase functions have been developed by using genetic
techniques such as RNAi and knockout animals. Although they
are powerful means of perturbing protein kinase-based
signaling pathways, these strategies have limitations, as the
knockout very often exhibits the opposite phenotype from the
one observed when only the catalytic activity of a kinase is
inhibited by using small molecules (Knight and Shokat, 2005)
(Table 1). A new era of molecularly targeted agents begun
when several chemical kinase inhibitors demonstrated powerful
clinical activity in tumors in which the target kinase was deregu-
lated (Cohen, 1999; Bogoyevitch and Fairlie, 2007), thus
ensuring a prominent position for chemical inhibition of protein
kinases in pharmacology. Several kinase inhibitor drugs have
been approved for treatments in oncology, and the success of
marketed small-molecule kinase inhibitors, such as Gleevec,
Irressa, and Tarceva, has recently attracted burgeoning interest
(Klein et al., 2005; Krause and Van Etten, 2005). However, the
target selectivity is a major concern because most small-mole-
cule kinase inhibitors target the highly conserved ATP-binding
pocket of this enzyme family, which is similar to ATP-binding
sites of nonkinases, resulting in unforeseen crossreactivities.
Less specific inhibitors would be expected to exhibit undesir-
able toxicities due to an off-target impact that would limit their
potential utility as therapeutic agents. For example, Gleevec,112 Chemistry & Biology 16, February 27, 2009 ª2009 Elsevier Ltd Aa great therapeutic success, has a relatively broad specificity
profile that was suggested to lead to side effects such as cardi-
otoxicity (Kerkela et al., 2006). Thus, there are compelling
reasons to identify new classes of protein kinase inhibitors that
do not target the ATP-binding site. Consequently, recent years
have witnessed considerable efforts to identify kinase inhibitors
with substantially different mechanisms of action (Table 2).
Some of them are allosteric inhibitors that alter kinase conforma-
tion and prevent protein substrate binding. As an illustration,
the crystal structure of a PD184352 (2-[2-chloro-4-iodo-phenyl-
amino]-N-cyclopropylmethoxy-3,4-difluoro-benzamide) analog
in complex with MEK1 and ATP shows that this compound binds
to a site adjacent to the ATP-binding pocket, and the low degree
of sequence conservation of this MEK1 region explains the high
selectivity of this kind of compound (Ohren et al., 2004). Several
classes of nanomolar, noncompetitive inhibitors of p38a kinase
have been described along with detailed structural characteriza-
tion of their binding sites. Remarkably, one of these compounds,
CMPD1 (20-fluoro-N-[4-hydroxyphenyl]-(1,10-biphenyl)-4-buta-
namide), is substrate selective, blocking the activity of p38a
against only a subset of its targets (Davidson et al., 2004). Other
inhibitors directly compete with protein substrate binding or
target the phosphorylation domain on the protein substrate
(Bogoyevitch and Fairlie, 2007).
Extensive studies have established that protein kinase
CK2 (formerly casein kinase 2) participates in the regulation of
fundamental cellular processes in eukaryotic cells. Indeed,
a significant proportion of the cellular phosphoproteome can
be attributed to the catalytic activity of CK2, and this ubiqui-
tously expressed protein kinase could be described as amaster-
mind enzyme, regulating crosstalk among multiple signaling
pathways critical for cell differentiation, proliferation, and
survival (Litchfield, 2003). CK2 is a tetramer composed of two
catalytic subunits, CK2a and CK2a0, and two regulatory, CK2b,
subunits. Genetic studies in yeast have shown that knockout
of CK2a and CK2a0 results in lethality, providing evidence for
an essential role of CK2 catalytic activity for survival (Glover,
1998; Lou et al., 2008). In mice, knockout of CK2a0 resulted inll rights reserved
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2003), and knockout of CK2b resulted in embryonic lethality,
revealing the functional importance of this regulatory subunit
(Buchou et al., 2003).
A variety of experimental evidence supports the view that
disregulated CK2 is functionally linked to cancer. Elevated
CK2 activity has been uniformly documented in different human
cancer types and has been correlated with aggressive tumor
Table 1. Different Strategies to Inhibit Protein Kinase Functions
Method Advantages Limitations
Antisense oligonucleotides Specifity Variable efficiency
In vivo uses
siRNA/shRNA Highly specific (isoform-specific targeting) Inhibit protein expression: all protein
functions are blocked
In vivo uses No successful clinical uses up to now
Knockout Highly specific (organ- and isoform-specific
targeting)
Irreversible
Physiologically relevant Redundancy may lead to absence
of phenotype
Microinjection of blocking antibodies Easy to set up Time consuming
Restricted to cell culture
Transfection of mutants/negative dominant Relatively fast Restricted to cell culture and simple
model organisms (yeast, zebrafish)
Physiological expression hardly achievable
Small molecules In vivo uses
Wide spectrum Development is costly and time consuming
Clinical use achievable Absolute specificity is rarely obtained
Reversibility: study of dynamic
phenomenons possible
Functions can be independently blocked
(i.e., kinase activity versus regulatory
subunit interaction)
siRNA, small interfering RNA; shRNA, small hairpin RNA.
Table 2. Selected Kinase Inhibitors with Different Mechanisms of Action
Protein-Kinase Compound Name Targeted Domain Reference
Akt AFQ5 Allosteric site Lindsley et al. (2005)
Compound 36 Allosteric site Siu et al. (2008)
BCR-Abl GNF-2 Myristate-binding site Adrian et al. (2006)
ON012380 Substrate-binding site Gumireddy et al. (2005a)
B-Raf Sorafenib Allosteric site Wilhelm et al. (2006)
ERK MAPK G8935 Allosteric site Han et al. (2005)
G0328 Allosteric site Han et al. (2005)
GSK3b TDZD Allosteric site Castro et al. (2008)
CMTK17 Allosteric site Conde et al. (2003)
IGFR-1 SBL02 Substrate-binding site Steiner et al. (2007)
ikB Kinase BMS-345541 Allosteric site Burke et al. (2003)
MEK1 U0126 Allosteric site Favata et al. (1998)
PD184352 Allosteric site Spicer et al. (2007)
PD098059 Allosteric site Favata et al. (1998)
PD318088 Allosteric site Ohren et al. (2004)
p38MAPK BIRB796 Allosteric site Pargellis et al. (2002)
CMPD1 Allosteric site Davidson et al. (2004)
Plk1 ON01910 Substrate-binding site Gumireddy et al. (2005b)
VEGFR AAL-993 Inactive conformation of ATP-binding site Manley et al. (2004)
TDZD, ThiaDiaZoliDinones; CMTK, ChloroMethylThienylKetones; AFQ: Amino-Functionnalized Quinoxaline.Chemistry & Biology 16, February 27, 2009 ª2009 Elsevier Ltd All rights reserved 113
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ReviewFigure 1. Different Modes of CK2 Inhibition by Small-Molecule Inhibitors
The catalytic (CK2a) and regulatory (CK2b) subunits are subjected to various interaction forces that lead to the reversible formation of different molecular forms
like the tetrameric holoenzyme and high-ordered oligomers (ring-like structures and filaments). This dynamic molecular organization offers several opportunities
to target the surface area of each subunit with small-molecule inhibitors.behavior (Tawfic et al., 2001; Faust and Montenarh, 2000).
Cancer cells bearing activated CK2 signaling pathways show
distinctive features such as growth advantage, enhanced
survival, and dynamic adaptation to stress. CK2 exerts a key
influence in the progression of oncogenesis by promoting
cell growth via the regulation of various oncogenes, tumor
suppressor proteins, and protection of antiapoptotic proteins
from caspase-mediated cleavage (Duncan and Litchfield,
2008). Of particular interest are reports demonstrating that
CK2 overexpression is an unfavorable prognostic marker in
prostate cancer (Laramas et al., 2007), in lung cancer (O-char-
oenrat et al., 2004), and in acute myeloid leukemia (Kim et al.,
2007). Additionally, several viral proteins are CK2 targets, indi-
cating a role for this kinase in viral infections (Wadd et al.,
1999; Souquere-Besse et al., 2002; Nuesch and Rommelaere,
2007; Medina-Palazon et al., 2007). Overexpression studies of
kinase-inactive CK2a and CK2a0, as well as antisense or siRNA
knockdown studies of the different CK2 subunits (CK2a, CK2a0,
or CK2b) showed effects on the cell cycle progression and
induction of an epithelial-to-mesenchymal transition in epithelial114 Chemistry & Biology 16, February 27, 2009 ª2009 Elsevier Ltd Acells (Yde et al., 2007; Deshiere et al., 2008). The viability of tar-
geting CK2 for cancer therapy was demonstrated when CK2
antisense-mediated diruption of CK2 activity in vitro led to the
induction of apoptosis (Faust et al., 2000; Wang et al., 2001) In
addition, it was also found that the same CK2a antisense oligo-
deoxynucleotide in xenograft models of prostate cancer
induced dose- and time-dependent tumor cell death (Slaton
et al., 2004). However, these studies also suggested the limita-
tions of CK2 knockdown strategies by showing variable effec-
tiveness to reduce CK2 expression levels (Duncan et al.,
2008). In contrast, small molecules can inhibit CK2 activity
without affecting other protein domains that might be affected
by a knockdown, and diverse strategies to inhibit CK2 functions
by small molecules have been explored in preclinical studies (for
an example, see Duncan et al., 2008) (Figure 1). Therefore, the
pharmacological inhibition of CK2 appears as a promissing
alternative strategy in deciphering its various cellular functions.
This review highlights recent advances that take advantage of
the peculiar molecular architecture of CK2 to discover small
molecules targeting different surface areas of CK2 subunits.ll rights reserved
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ReviewFigure 2. Representation of the CK2a Structure Illustrating Its Different Surface Areas Targeted by New Potent Inhibitors
The phosphate anchor domain is in blue, and key structural elements, like the lysine-rich cluster, the activation segment, and the N-terminal region, are in gray.
The CK2b-binding site formed by the b4/b5 loop is in yellow.ATP-Competitive Inhibitors
Thedegree of homology across the entire family of humanprotein
kinases is relatively high, especially within their catalytic cores.
Nonetheless, themajority of small-molecule protein kinase inhib-
itors interact with the conserved ATP-binding site of their target.
These compounds mainly act as adenine mimics, targeting the
ATP-binding pocket by virtue of a complex network of hydro-
phobic interactions and hydrogen bonding. However, even
though major specificity determinants, such as a small hydro-
phobic pocket located at the back of the ATP-binding site
commonly blocked by a side chain of a so-called ‘‘gatekeeper’’
residue, are known in somecases, a complete specificity of these
compounds is hard to achieve, and in vivo assessment of
compound selectivity remains a challenge (Cohen and Goedert,
1998; Knight and Shokat, 2005; Fabian et al., 2005).
In the case of CK2, a number of different classes of chemical
compounds that target its active site have been characterized
asATP-competitive inhibitors, such as halogenated compounds,
4,5,6,7-tetrabromobenzimidazole (TBB) derivatives (Pagano
et al., 2004), condensed polyphenolic derivatives (Meggio et al.,
2004), and indoloquinazoline-based compounds (Sarno et al.,
2003; Vangrevelinghe et al., 2003). They are efficient in the lowChemistry & Biologmicromolar range and display high specificity for CK2. Some of
them are cell permeable but differ in their physiological effects
in cells, probably reflecting their off-target activity toward other
ATP-binding proteins with similar ATP-binding sites (Sarno
et al., 2002; Duncan et al., 2008).
Alternative Strategies to Inhibit CK2
There is now an increasing interest in identifying more specific
next-generation CK2 inhibitors that do not directly compete
with ATP and exhibit different mechanisms of action (Figure 2).
Non-ATP-Competitive CK2 Inhibitors
Small-molecule inhibitors that block CK2-dependent phosphor-
ylations without directly targeting ATP binding have been
recently identified (Figure 2 and Table 3).
Targeting the CK2 Substrate. A distinctive feature of CK2,
which could be exploited to inhibit its activity, is its acidophilic
substrate specificity. Peptides that inhibit CK2-catalyzed phos-
phorylation by binding to the acidic phosphoacceptor site on
CK2 substrates have been identified by screening of a random
cyclic peptide phage library by using the HPV-16 E7 oncopro-
tein as a target (Perea et al., 2004). One active peptide, P15,
abrogates the phosphorylation of the E7 protein by CK2 (Tabley 16, February 27, 2009 ª2009 Elsevier Ltd All rights reserved 115
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TBB, 4,5,6,7-tetrabromo-1H-benzotriazole; POMs, polyoxometalates; W16, podophyllotoxine indolo-analog.3). In addition, when fused to the cell-penetrating peptide Tat,
P15 behaved as a proapoptotic peptide in tumor cells and ex-
hibited antitumor activity after systemic administration both in
cancer animal models and in a clinical trial on patients with
cervical malignacies (Perera et al., 2008; Perea et al., 2008).
However, it is not clear whether P15 has a specific or global
effect on CK2-mediated phosphorylations in living cells.
Furthermore, a direct link between the proapoptotic and anti-
tumor properties of this peptide and the targeting of the phos-
phoacceptor domain in relevant physiological CK2 substrates
remains to be established.
Targeting an Exosite on CK2a. Using high-throughput
screening of highly diverse chemical libraries, polyoxometa-
lates (POMs) belonging to a unique class of inorganic
compounds have been identified as potent CK2 inhibitors
(Prudent et al., 2008). POMs are complexes of early-transition
metal ions (mainly M = Vv, Movi, Wvi) and oxo ligands (Pope,
2003), which are generated in solution by condensation reac-
tions of the oxo anion MO4
n (Table 3). Several polyoxometa-
late derivatives inhibit CK2 in the nanomolar range and exhibit116 Chemistry & Biology 16, February 27, 2009 ª2009 Elsevier Ltd Ahigh specificity for CK2. Steady-state kinetic analysis showed
a mixed inhibition of CK2 by POMs with respect to ATP,
indicating that these compounds are not ATP-competitive
inhibitors. Also, POMs are not peptide substrate-binding site-
directed inhibitors. Different biochemical analysis suggested
that POMs bind outside the ATP/peptide-binding pocket and
the CK2a/CK2b interface. Further analysis with proteolytic
degradation of the CK2a-POM complex and site-directed
mutagenesis revealed that inhibitor-interacting regions contain
key structural elements, like an activation segment (Figure 2). In
CK2, this segment is stabilized by contacts to the N-terminal
region that maintain CK2 in an active state (Niefind et al.,
2001; Duncan and Litchfield, 2008). Thus, docking of POMs
to the activation segment may disrupt these contacts, locking
CK2 in an inactive conformation, and although the intra-
molecular interactions between the activation loop and
the N-terminal segment are very strong they are easily over-
come by low concentrations of POMs. Therefore, POMs are
effective CK2 inhibitors in terms of both efficiency and selec-
tivity, interacting with CK2 in a unique way. The bindingll rights reserved
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an exploitable mechanism for developing potent drugs with
desirable properties, such as enhanced selectivity relative to
ATP-mimetic inhibitors.
Targeting the CK2b Subunit
CK2 has a molecular architecture of multisubunit protein kinases
with a quaternary structure consisting of two catalytic subunits
(CK2a and CK2a0) and two regulatory subunits (CK2b) (Pinna,
2002). Consequently, different strategies based on this molec-
ular architecture can be exploited to inhibit CK2 functions
(Figure 2 and Table 3). For example, although CK2 catalytic
subunits possess a significant basal activity, CK2b is a central
component responsible for docking and/or recrutment of CK2
substrates or protein partners, modulating substrate selectivity
and catalytic activity (Bibby and Litchfield, 2005). This raises
the possibility that CK2a could be locally and transiently
recruited into multimolecular complexes in which the CK2b
dimer serves as a scaffold for high-affinity interactions with
substrate or nonsubstrate protein partners (Litchfield, 2003;
Filhol et al., 2004). In mice as well as in Caenorhabditis elegans,
a functional loss of CK2b is lethal, illustrating the dramatic
phenotypic consequences of disrupting the interactions in which
this protein is involved. Therefore, reagents that could block
interactions between CK2b and specific partners in vivo would
help to elucidate the functional significance of CK2 in cell
signaling pathways. Using a two-hybrid screening of a combina-
torial peptide aptamer library, we could isolate a peptide
(P1 peptide) that binds with high affinity (KD = 0.4 mM) to the
N-terminal domain of CK2b without disrupting the formation of
the CK2 holoenzyme (Table 3) (Martel et al., 2006). This is
comparable with KD values for other biologically important inter-
actions, including those between various SH2 domains and
receptor-mimicking phosphopeptides (KDz 0.3–130 mM) (Lad-
bury et al., 1995; Zhou et al., 1995). Expression of P1 peptide in
different mammalian cell lines activates p53 phosphorylation on
Ser15, induces an upregulation of p21, and triggers apoptosis
through the recruitment of a p53-dependent apoptosis pathway
(Martel et al., 2006). The crystal structure of CK2b revealed its
zinc finger-mediated dimerization and the presence of solvent-
exposed and conserved residues that may represent binding
surfaces for multiple protein ligands previously identified as
CK2b partners (Chantalat et al., 1999; Grein et al., 1999; Filhol
et al., 2004). The significant sequence homology between P1
and the murine cytomegalovirus IE2 protein raises the possibility
that these two ligands might interact with a common domain on
CK2b. Indeed, the IE2 protein is known to interact with the
N-terminal region of CK2b and to trigger cell apoptosis (Shimada
et al., 2004; Chiou et al., 2001). Therefore, binding of P1 peptide
or viral proteins to the N-terminal domain of CK2bmay compete
for a binding site on the protein for endogenous ligands. It is
noteworthy that most drugs and leads achieve their activity by
competing for a structurally defined binding site on a protein
with endogenous ligands (Hopkins and Groom, 2002). Thus,
specifically targeting the regulatory CK2b subunit could repre-
sent a strategy to block specific interaction between CK2 and
some of its partners in vivo. In addition, this study provides the
first peptide lead that can be exploited as a guide for the design
of small chemical molecules for CK2b-targeted inducers of
apoptosis.Chemistry & BiologDisrupting the Subunit Interaction
Protein-protein interactions play a key role in cellular signal
transduction pathways. Albeit challenging, the ability to interfere
with specific protein-protein interactions has already provided
a powerful means of influencing the functions of selected
proteins within the cells. The CK2b subunit enhances CK2
signaling by bringing CK2a into proximity with its partners and
substrates. In addition, the crystal structure of the CK2 holoen-
zyme complex as well as live cell imaging studies (Niefind et al.,
2001; Filhol et al., 2003) suggested that CK2 subunits can
coexist in the cell without forming the holoenzyme complex,
even though they readily bind with high affinity in vitro (Guerra
et al., 1999; Filhol et al., 2004). Thus, this intersubunit flexibility
and the existence of a subtle equilibrium between different
forms of CK2 subunits is a likely point of regulation that should
be amenable to drug-discovery efforts. Structural properties of
the holoenzyme showed that the CK2 subunit interface is rela-
tively small, thus offering attractive opportunities for the identifi-
cation of small molecules that modulate this interaction. In the
CK2 holoenzyme structure, a segment located in the CK2b tail
points away from the protein core and forms a b hairpin loop
that inserts deep into a shallow hydrophobic groove present in
the b4/b5 sheets of CK2a (Niefind et al., 2001). Site-directed
mutagenesis and functional assays have revealed that only
a small set of primary hydrophobic residues present in this
segment of CK2b dominates affinity. Further characterization
of these hotspots led to the structure-based design of CK2b-
derived cyclic peptides that are potent inhibitors of the CK2
subunit interaction (Table 3). One of these conformationally
constrained cyclic peptides, Pc peptide, was able to efficiently
antagonize the assembly of the CK2 holoenzyme complex and
to strongly affect its substrate preference (Laudet et al., 2007).
The Laudet et al. study was the first step to set the framework
for the discovery and development of chemical inhibitors of
this interaction. The existence of a druggable pocket within the
interface area of CK2 was corrrobored by a recent structural
study showing that one of the oldest, albeit nonspecific, CK2
inhibitors, D-ribofuranosylbenzimidazole (DRB), binds, in addi-
tion to the canonical ATP cleft, to an allosteric site that was iden-
tified in the CK2a/CK2b interface. Inhibition kinetic studies
demonstrated the dual binding mode of this inhibitor. However,
the affinity of DRB for this binding site is not high enough to
inhibit the subunit interaction (Raaf et al., 2008). Screening of
a library of podophyllotoxine indolo-analogs led to the identifica-
tion of the first chemical inhibitors of this interaction (Laudet
et al., 2008). Three lead compounds were shown to block the
interaction between the two CK2 subunits through direct binding
to CK2a (the structure of the most potent compound [W16] is
shown in Table 3). Interestingly, kinetic analysis revealed that
these compounds trigger a noncompetitive inhibition of CK2a
without interfering with the ATP cleft. This inhibition was allevi-
ated by CK2b or by the CK2b-derived cyclo peptide (Pc
peptide), suggesting that this class of inhibitors binds to the
CK2a/CK2b interface in/near the CK2b-binding pocket on
CK2a. As this binding site is located close to the ATP-binding
pocket, docking of the compounds into this binding site may
induce subtle allosteric conformational changes in CK2a that
affect its activity. More recently, using a structure-based virtual
screening approach, we could identify a cluster of chemicaly 16, February 27, 2009 ª2009 Elsevier Ltd All rights reserved 117
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ant properties (manuscript in preparation). Structural insights
from CK2a-inhibitor complexes would be essential to reveal
the mode of CK2 inhibition by these compounds and may
provide a platform for the structure-based design of a next
generation of inhibitors.
The existence of higher-ordered quaternary structures of CK2
holoenzymes (ring-like structures and filaments) has been
observed both in solution (Glover, 1986; Valero et al., 1995)
and in CK2 holoenzyme crystals (Niefind and Issinger, 2005).
Importantly, the catalytic activity was shown to be significanty
enhanced in the ring-like structures or downregulated in the fila-
ments (Valero et al., 1995). Formation of this supramolecular
oligomers depends on electrostatic interactions that are modu-
lated by spermine or MgCl2 concentrations (Leroy et al., 1994),
suggesting that CK2 may exist in vivo in the form of inactive or
active oligomers that could be targeted by small-molecule inhib-
itors (Figure 1).
Summary and Outlook
CK2 is endowed with specific structural features that have moti-
vated the current efforts in this exciting field of early drug
discovery. New ways to screen for, or design, inhibitors of CK2
on the basis of a detailed understanding of its catalytic and regu-
latory properties is likely to become more and more important.
The design, synthesis, and testing of compounds that interact
differentially with the surface areas of CK2a outside its catalytic
gorge region already led to the identification of new potent inhib-
itors (Figure 2 and Table 3). They promise exciting opportunities
by exploiting new mechanisms of action that may allow for
greater specificity. Obviously, structural and biophysical charac-
terization of their binding sites is urgently needed. Interferingwith
specific interactions betweenCK2b and some of its partners with
peptide ligands or chemical compounds could also provide an
efficient strategy for disrupting CK2 functions. The dynamic
CK2 subunit interaction is also a likely point of regulation. There-
fore, structure-based design of CK2b-derived peptides that
antagonize the CK2 subunit interaction has been utilized to
produce pharmacophore and scaffold structures, allowing for
the identification of chemical inhibitors of this interaction by
in silico screening. It is expected that these compounds will be
substrate selective, inhibiting the activity of the kinase against
a subset of its substrates.
Overall, the emergence of a new generation of CK2 inhibitors
provides a fondation for a new paradigm for CK2 inhibition and
a unique opportunity to predict how their different modes of inhi-
bition will translate into phenotypes in a physiological setting.
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